Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The employee awards vest over time and could add up to 128,000 common shares if exercised.

Rhea-AI Summary

Inhibikase Therapeutics (IKT) granted stock options covering up to 128,000 common shares to two newly hired non-executive employees, effective September 30, 2026. The grants were approved as employment inducements under Nasdaq Listing Rule 5635(c)(4) through the company's 2026 Inducement Equity Plan.

The options have an exercise price of $2.055 per share, equal to the stock's closing price on the effective date, and a ten-year term. Vesting begins with 25% on the first anniversary of the effective date, followed by the remaining 75% in 36 equal monthly installments. The grants are subject to the plan and award agreements.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options covering up to 128,000 shares at $2.055 per share create potential dilution if exercised.

Key Figures

Options granted: 128,000 shares Exercise price: $2.055 per share Option term: 10 years +1 more

Options granted

128,000 shares

Aggregate options granted to two newly hired non-executive employees

Exercise price

$2.055 per share

Equal to the common stock closing price on the Effective Date

Option term

10 years

Term of the inducement options

Vesting schedule

25% at the first anniversary; remaining 75% in 36 equal monthly installments

Based on the Effective Date

Historical Context

1 past event · Latest: Jul 02

1 event

1. Jul 02

   inducement grants

   24h Move

   -0.5%

   Earlier same-plan grants covered 981,243 shares for seven newly hired employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options

1 terms

non-qualified stock options financial

"granted non-qualified stock options to purchase up to an aggregate of"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WILMINGTON, Del., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 128,000 shares of the Company’s common stock to two newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of September 30, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $2.055 per share, which is equal to the closing price of the Company’s common stock on the Effective Date. The options have a ten year term, with 25% vesting on the first anniversary of the Effective Date and the remaining 75% vesting in 36 equal monthly installments thereafter. The options are subject to the terms and conditions of the Inducement Plan approved by the Company’s Board of Directors in March 2026 and the terms and conditions of award agreements covering the grants.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.

Contacts:
Investor Relations:
Michael Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many employee stock options did Inhibikase Therapeutics grant and at what exercise price?

Inhibikase granted options to purchase up to 128,000 common shares to two newly hired non-executive employees at an exercise price of $2.055 per share. The grants took effect September 30, 2026, and the exercise price equals the stock's closing price that day.

What is the vesting schedule for IKT's September 2026 inducement options?

The options vest 25% on the first anniversary of September 30, 2026, with the remaining 75% in 36 equal monthly installments thereafter. They have a ten-year term and are subject to the 2026 Inducement Equity Plan and the applicable award agreements.